Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -3.41% |
|
-15.42% | -8.11% |
07/06 | Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target | MT |
29/05 | HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 139.3 | 60.88 | 59.43 | 68.1 | - | - |
Enterprise Value (EV) 1 | 139.3 | 60.88 | 59.43 | 68.1 | 68.1 | 68.1 |
P/E ratio | -2.02 x | -2.31 x | -2.15 x | -1.79 x | -1.65 x | -1.27 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | -1.4 x | - | -1.22 x | -1.14 x | -0.96 x |
FCF Yield | - | -71.7% | - | -81.7% | -88.1% | -105% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 22,036 | 28,989 | 32,122 | 40,058 | - | - |
Reference price 2 | 6.320 | 2.100 | 1.850 | 1.700 | 1.700 | 1.700 |
Announcement Date | 30/03/22 | 23/03/23 | 26/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -28.6 | -43.55 | -50.72 | -61.48 | -73.59 | -90.41 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -11.72 | -21.4 | -25.79 | -36.94 | -50.93 | -73.43 |
Net income 1 | -12.07 | -16.25 | -21.4 | -25.79 | -36.91 | -50.93 | -73.43 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -7.350 | -3.130 | -0.9100 | -0.8600 | -0.9500 | -1.030 | -1.338 |
Free Cash Flow 1 | - | - | -43.64 | - | -55.67 | -59.97 | -71.2 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 07/05/21 | 30/03/22 | 23/03/23 | 26/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -11.81 | -9.413 | -12.21 | -12.62 | -9.3 | -8.973 | -11.82 | -14.74 | -15.19 | -14.1 | -15.09 | -16.08 | -15.49 | -18.27 | -19.19 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -7.339 | -3.713 | -5.877 | -6.625 | -5.182 | -6.172 | -4.726 | -6.749 | -8.141 | -9.151 | -8.69 | -9.454 | -9.68 | -12.27 | -13.19 |
Net income 1 | -7.545 | -3.838 | -5.752 | -6.625 | -5.182 | -6.172 | -4.726 | -6.749 | -8.141 | -9.151 | -8.69 | -9.454 | -9.696 | -12.27 | -13.19 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4000 | -0.1700 | -0.2500 | -0.2900 | -0.2000 | -0.2100 | -0.1600 | -0.2200 | -0.2700 | -0.2700 | -0.2350 | -0.2283 | -0.2150 | -0.2600 | -0.2800 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 30/03/22 | 11/05/22 | 09/08/22 | 14/11/22 | 23/03/23 | 04/05/23 | 08/08/23 | 02/11/23 | 26/03/24 | 07/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -43.6 | - | -55.7 | -60 | -71.2 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 0.03 | 0.17 | - | 0.04 | 0.07 | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 07/05/21 | 30/03/22 | 23/03/23 | 26/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.11% | 6.81Cr | |
+16.49% | 12TCr | |
+21.73% | 12TCr | |
+20.84% | 2.66TCr | |
-21.81% | 1.99TCr | |
-16.89% | 1.63TCr | |
-44.74% | 1.55TCr | |
-18.81% | 1.55TCr | |
+62.72% | 1.48TCr | |
+3.09% | 1.37TCr |
- Stock Market
- Equities
- CGTX Stock
- Financials Cognition Therapeutics, Inc.